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index date for the comparator group was randomly chosen to reduce selection bias. 
A 1-year continuous health plan enrollment was required before and after the index 
date for both groups. Study outcomes, including health care costs and utilizations, 
were compared between the disease and comparator groups using 1:1 propensity 
score matching (PSM). Results: Eligible patients (N= 384,596) were identified for 
the prostate cancer and comparison cohorts and after applying PSM, a total of 
112,693 patients were matched from each group and the baseline characteristics 
were well-balanced. Patients diagnosed with prostate cancer were more likely to be 
hospitalized (75.41% vs. 2.46%, p< 0.01), and report more emergency room (9.30% vs. 
5.45%, p< 0.01), outpatient (99.77% vs. 61.15%, p< 0.01) and pharmacy visits (85.65% 
vs. 63.77%, p< 0.01). Patients diagnosed with prostate cancer also incurred higher 
costs for inpatient ($2,216 vs. $695, p< 0.01), emergency room ($92 vs. $51, p< 0.01), 
outpatient ($3,364 vs. $1,462, p< 0.01), pharmacy ($582 vs. $413, p< 0.01) and total 
costs (6,162 vs. $2,571, p< 0.01) compared to the comparator group. ConClusions: 
Patients diagnosed with prostate cancer were associated with a higher burden of 
illness compared to their matched controls during a period of 12 months.
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objeCtives: Everolimus and axitinib are approved to treat patients with metastatic 
renal cell carcinoma (mRCC) following failure on various first-line therapies. This 
analysis assessed the cost of care with everolimus versus axitinib for second-line 
mRCC patients from a Canadian payer perspective. Methods: Costs considered 
in this analysis included those related to drug acquisition and adverse events (AEs). 
Drug acquisition costs were based on the Ontario wholesaler price. Adverse event 
costs were based on the Ontario Case Costing Initiative and literature. Drug costs, 
adjusted for dose intensity, and AE costs, based on daily incidence rates, accrued 
for the duration of treatment in each arm; the sums of these costs were compared 
across treatments. The mean dose intensities, treatment durations and rates of 
AEs in the treatment arms were the calculated from trial data. Scenario analyses 
are presented to estimate the range of costs within the treatment arms. Costs are 
presented in 2011 Canadian dollars. Results: In the base case analysis, the total 
cost of treatment with everolimus was estimated to be $24,931 while the total cost 
of treatment with axitinib was $39,010. The primary driver of the cost discrepancy 
was axitinib’s high dose intensity, resulting in high drug acquisition costs. Despite 
analysis limitations, the trend of the results remained consistent across scenario 
analyses. When treatment duration was estimated from median progression-free 
survival estimates in each study’s post-sunitinib populations, the total cost of treat-
ment with everolimus was $8,339 less than with axitinib. Sensitivity analyses that 
assumed equivalent treatment durations between each arm also demonstrated 
lower overall treatment costs for everolimus patients. ConClusions: The analysis 
demonstrates that everolimus provides a less costly treatment option than axitinib 
for patients requiring second-line therapy. Significant uncertainty remains regard-
ing axitinib’s treatment duration and dosing, which could result in higher costs to 
the health care system compared to everolimus.
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objeCtives: Ipilumumab is a clinically proven treatment option for pre-treated 
metastatic melanoma (MM). Ipilumumab has clearly demonstrated survival ben-
efit, that is prolonged in a proportion of the responding patients. Karweit J and 
colleagues (2012) demonstrated that mean overall survival (OS) can be particularly 
useful for agents with a right-skewed survival curve where a subset of patients 
respond to treatment with long term survival. The research has demonstrated that 
several agents, including ipilimumab for MM, bevacizumab for non-small cell lung 
cancer, sorafenib for hepatocellular carcinoma, lenalidomide for multiple mye-
loma and trastuzumab for metastatic breast cancer (among others) have shown 
greater mean OS improvement than median OS improvement, reflecting the long 
term survival benefit for some patients. In this analysis we select oncologic agents 
that have demonstrated mean OS benefit in the above mentioned study and have 
received license in Mexico. We compare the relative economic value delivered by 
each asset, which broadly represent the therapeutic oncologic class. Methods: 
The economic value of the analogues is estimated for the Mexican private per-
spective in terms of cost per month of mean OS versus comparators. The analy-
sis relies on the cost to treat to mean progression by the months of mean OS 
improvement. Results: Cost per month of OS for ipilimumab ($15,993 USD) when 
compared to bevacizumab, sorafenib, trastuzumab, sunitinib, lenalidomide and 
vemurafenib is below the average relative cost of the assets (range from $35,871 
to $9,845 USD). ConClusions: This study demonstrates that ipilimumab is a 
competitive asset in terms of value for money. The analysis allows to evaluate 
within a clear and robust analytical framework, the reimbursement decisions 
across the oncologic therapeutic class in Mexico.
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objeCtives: To measure the costs of two pilot interventions within the National 
Institutes of Health-funded Centers for Population Health and Health Disparities 
(CPHHD) designed to improve health outcomes in medically underserved commu-
estimates do not count multiple episodes of the same event. Costs of managing 
each adverse event were obtained from the literature and averaged across west-
ern European countries (UK, Germany, France, Italy, Belgium, Spain, Sweden, and 
Switzerland), where available. The costs were inflated to 2012 Euros (€ ). Results: 
Expected per-patient costs of managing adverse events within the first year of treat-
ment among patients with advanced breast cancer receiving EVE+EXE were € 730. 
Among patients receiving capecitabine, docetaxel, or doxorubicin as single-agent 
chemotherapy, expected per-patient costs were € 1721, € 2390, and € 1230, respectively. 
The most costly adverse event for patients treated with EVE+EXE was anemia (€ 152 
per patient). The most costly adverse event for patients treated with capecitabine, 
docetaxel, or doxorubicin was lymphocytopenia (€ 861 per patient), neutropenia 
(€ 821 per patient), and leukopenia (€ 382 per patient), respectively. ConClusions: 
Expected costs of managing adverse events in patients with HR+/HER2- advanced 
breast cancer receiving EVE+EXE are about one-half to one-third of the costs for 
those receiving chemotherapies. This economic consideration can have important 
implications for health care spending in the advanced breast cancer setting.
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objeCtives: To estimate the economic impact of managing chemotherapy patients 
at risk of neutropenia and eligible to receive Granulocyte-Colony Stimulating Factor 
(G-CSF) with lipegfilgatrim (LONQUEX, a new long-acting G-CSF) rather than peg-
filgastrim in Spain. Methods: Both the BIA and CMA were conducted from the 
Spanish-payer’s perspective: they included direct drug cost, administration, neutro-
penic events and adverse event costs, but did not consider indirect costs. The drug 
acquisition cost of lipegfilgatrim used in the model was based on the anticipated 
price of lipegfilgatrim at the time of launch in Spain. All costs were expressed in 
EUROS-2013. A range of sensitivity, scenario and threshold analyses were performed. 
An additional analysis was performed within the BIA to explore the trend towards 
fewer dose modifications in the lipegfilgatrim arm of the XM22-03 trial. Results: 
The CMA shows that treating a patient with lipegfilgatrim instead of pegfilgrastim 
resulted in a cost saving of 650,06€ . At the population level, the BIA predicts that 
cost savings could range from 113.166€ in year 1 to 678.995€ in year 5, totaling to 
2.489.648€ over five years. Furthermore, the BIA shows a potential to avoid 50 dose 
modifications with the use of lipegfilgatrim instead of pegfilgrastim. The model is 
most sensitive to the cost of pegfilgrastim and lipegfilgatrim, but results are robust, 
with the model estimating cost savings over a wide range of inputs. When the trend 
towards decreased NE and increased AE with lipegfilgatrim vs pegfilgrastim reported 
in the XM22-03 trial is explored, cost savings was about 30% compared to the default 
scenario, reaching 3.208.619 € ., mainly due to decreased NE costs ConClusions: 
Lipegfilgatrim is cost-saving compared with pegfilgrastim. These savings are con-
firmed across a wide range of input values.
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objeCtives: There are relatively few treatment options for pre-treated metastatic 
melanoma (MM) patients. Clinicians have recently been provided access to a new 
option, ipilumumab that has demonstrated long-term survival benefits, in a subset 
of patients. Karweit J and colleagues (2012) present data to support the use of mean 
OS for agents with a right-skewed survival curve, where a subset of patients respond 
to treatment with long term survival -as is the case for ipilimumab. The research 
presents data for several oncology agents: ipilimumab for MM, bevacizumab for non-
small cell lung cancer, sorafenib for hepatocellular carcinoma, lenalidomide for mul-
tiple myeloma, trastuzumab for metastatic breast cancer and vemurafenib for MM. 
The data reveals a greater mean OS improvement than median OS improvement, 
since mean OS accurately captures the complete survival benefits. In this analysis 
we select agents from the Krweit J et al study and who have received regulatory 
authorization in Colombia, to compare their relative economic value. Methods: 
The economic value of each asset is presented in terms of cost per month of mean 
OS within the Colombian health care payer perspective. The analysis uses the cost 
to treat to mean progression of each asset divided by the months of mean overall 
survival improvement using current list prices of assets. Results: Ipilimumab in 
comparison to bevacizumab, sorafenib, trastuzumab, sutinib, lenalidomide, and 
vemurafenib demonstrates a clinical and economic relative value. The cost per mean 
overall survival month gained for ipilumumab ($39,344,362 COP) is below the average 
of the comparator assets (range from $60,226,690 to $20,166,226). ConClusions: 
The relative clinical and economic value of ipilumumab in the context of a variety 
of oncologic assets is clearly documented. This data provides health care decision 
makers critical data when determining coverage of oncologic treatments.
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objeCtives: To examine the economic burden and health care utilizations of pros-
tate cancer patients in the U.S. veteran population. Methods: Patients diagnosed 
with prostate cancer (ICD-9: 185.xx) were identified from the U.S. Veterans Health 
Administration (VHA) Medical SAS dataset from October 1, 2009 through September 
30, 2011. The first diagnosis date was defined as the index date. A comparator group 
was created by identifying patients without prostate cancer but with the same age, 
region, gender, index year, and matched baseline Charlson Comorbidity Index. The 
